Evidence map›Paper›PMID 41454327›Full record

ArticleBMC cancer2025

Network pharmacology analysis and in vitro experimental validation of liriodenine against non-small cell lung cancer.

Jing Yang, Yichu Sun, Fei Liang, Ziqiang Shen, Yun Zhou, Jiangrui Zhu, Wen Sun, Youyou Xia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing Yang *Department of Radiation Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, 222000, China.
Yichu Sun *Department of Radiation Oncology, The First People's Hospital of Lianyu ngang/Lianyungang Clinical College of Nanjing Medical University, Liany ungang, Jiangsu, 222000, China.
Fei Liang *Department of Radiation Oncology, The First People's Hospital of Lianyu ngang/Lianyungang Clinical College of Nanjing Medical University, Liany ungang, Jiangsu, 222000, China.
Ziqiang ShenDepartment of Radiation Oncology, The First People's Hospital of Lianyu ngang/Lianyungang Clinical College of Nanjing Medical University, Liany ungang, Jiangsu, 222000, China.
Yun ZhouDepartment of Radiation Oncology, Southeast University Affiliated Xuzhou Central Hospital, Xuzhou, China.
Jiangrui ZhuDepartment of Radiation Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, 222000, China.
Wen SunLaboratory of Precision Medicine, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, 222000, China.
Youyou XiaDepartment of Radiation Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, 222000, China. xia.youyou@njmu.edu.cn.

Funding

Application and Management Standards for Treatment Equipment for Non-Small Cell Lung Cancer JSYGY-1-2023-03(11)Jiangsu Provincial Construction of Key Medical Disciplines JSDW202234Key Laboratory Project of New Drug Research and Clinical Pharmacy in Jiangsu Province XZSYSKF2023013Lianyungang City Science and Technology Program SF2347
6 · The paper itself

Abstract

objectiveLiriodenine, a natural aporphine alkaloid from various medicinal plants, has shown antitumor activity in several cancers. However, its role and mechanisms in non-small cell lung cancer (NSCLC) remain unclear.

methodsPotential targets of liriodenine and NSCLC were retrieved from public databases. Core targets were identified using random forest and the Least Absolute Shrinkage and Selection Operator regression algorithms. Molecular docking and dynamics simulations assessed the binding affinity and stability between liriodenine and its targets. In vitro assays were performed in A549 cells. Cell viability, proliferation, migration, and apoptosis were evaluated by CCK-8, colony formation, wound healing, and flow cytometry, respectively. Western blot was used to measure Transforming Growth Factor Beta 1(TGF-β1)expression.

resultsSixty-five overlapping targets were identified. Computational analysis showed that liriodenine strongly and stably binds TGF-β1. In vitro, liriodenine significantly inhibited proliferation and migration, induced apoptosis, and downregulated TGF-β1 expression in a dose-dependent manner. These effects provide evidence suggesting the involvement of the TGF-β1/Epithelial-Mesenchymal Transition pathway.

conclusionThis study provides both computational and experimental evidence that liriodenine inhibits the growth and migration of NSCLC cells and promotes apoptosis by suppressing TGF-β1. These findings highlight its potential as a natural candidate for targeted therapy against NSCLC.

Indexed as

AporphinesCarcinoma, Non-Small-Cell LungLung NeoplasmsNetwork PharmacologyA549 CellsApoptosisCell MovementCell ProliferationCell SurvivalEpithelial-Mesenchymal TransitionHumansMolecular Docking SimulationMolecular Dynamics SimulationTransforming Growth Factor beta1AporphinesliriodenineTransforming Growth Factor beta1Experimental validationLiriodenineMachine learningNetwork pharmacologyNon-small cell lung cancer

Identifiers

PMID41454327
PMCPMC12860169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.